(Reuters) – Europe’s medicines regulator said on Friday an antibody drug combination developed by Eli Lilly and Co can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness.
The recommendation can now be used as guidance in individual European nations on the possible use of the combination of bamlanivimab and etesevimab, before a marketing authorisation is issued, the European Medicines Agency said. (https://bit.ly/3kMpkZr)
(Reporting by Indranil Sarkar in Bengaluru; Editing by Shounak Dasgupta)
